Europium Lithosilicates LiEuSiN and LiEuSiO-Crystal Structures and Luminescence.

With LiEuSiN, the end member of the solid-solution series set up by substituting the divalent cation in the well-known host materials LiCaSiN and LiSrSiN with Eu(II) could be synthesized and described by means of single-crystal X-ray diffraction and single-grain luminescence spectroscopy. The new compound crystallizes isotypically to LiCaSiN and LiSrSiN in cubic space group 3Ì… (no. 205) with a lattice parameter of = 10.

Polymorphism and polymorph-dependent luminescence properties of the first lithium oxonitridolithosilicate LiSiNO:Eu.

Building on studies of monoclinic LiSiNO, a polymorph, β-LiSiNO, with a previously unknown structure type was synthesized. The β-phase crystallizes in the orthorhombic space group (no. 61) with lattice parameters of = 18.

The crystal structure and luminescence properties of the first lithium oxonitridolithosilicate LiSiNO:Eu.

The compound LiSiNO:Eu was synthesized in high temperature solid-state reactions in weld shut tantalum ampules and the crystal structure of LiSiNO has been determined by single-crystal X-ray diffraction. It crystallizes in the monoclinic space group 2/ (no. 15) with the lattice parameters = 1049.

[State of the therapy of hemangiopericytoma].

To informations from literature 700 patients with a hemangiopericytoma can be expected globally until the year 1988. Actually there is no uniform therapeutic procedure for this cancer disease. The own therapeutic strategy is represented, successfully applied to three patients: Actually we consider optimal the combination of surgical extirpation with following radiotherapy of the former tumor bed with a minimum target dose of 45 Gy to guarantee a total remission and a long-time survival.

[Prognosis and therapy of malignant non-Hodgkin's lymphoma].

Rarely low malignant Non-Hodgkin-lymphomas (NHL) can be attended curatively. An alternative to hitherto applied chemotherapy in advanced stages is the retarded therapeutic proceeding in the so-called "indolent" NHL. However, the optimal therapeutic regimen is unknown.

[Cyclic nucleotide concentration changes in different tumors and therapeutic success through increasing the cAMP level].

Changes in the concentration of cyclic AMP as well as cyclic GMP were measured in different murine tumors and in human tumors of varying malignancy. The quotient of cAMP and cGMP seems to be an important parameter for the molecular-biological derangement. Because of the recently much discussed importance of cAMP and cGMP in the immune defence the changes in the concentration of both nucleotides were measured in the T-lymphocytes of tumor patients.

Changes in mouse skin cyclic nucleotides during chemical carcinogenesis and tumor response to treatment with BCG, L-Dopa and cyclic DBAMP.

During chemical carcinogenesis by 9, 10-dimethyl 1,2-benzanthracene the cyclic AMP and GMP content was measured in the skin of mice. The tissue of the developing skin tumor is characterized by an elevated cyclic GMP- and a lowered cyclic AMP level. Consequently the quotient of cyclic AMP and GMP is greatly lowered and is discussed as a crucial factor of cell derangement.